AbCellera Biologics Inc. ABCL Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from AbCellera Biologics Inc.’s reported figures.
Based on trailing twelve months.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s return on assets?
- AbCellera Biologics Inc. (ABCL) reported return on assets of -10.9% in Q1 2026.
- How has AbCellera Biologics Inc.'s return on assets changed year-over-year?
- AbCellera Biologics Inc.'s return on assets increased by 9.2% year-over-year, from -12% to -10.9%.
- What is the long-term trend for AbCellera Biologics Inc.'s return on assets?
- Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s return on assets has grown at a -6.6% compound annual growth rate (CAGR), from 13.2% to -10.8%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.